Drugstore cowboys.Amgen Inc., the world's biggest biotechnology company, is lobbying more than 200 of its U.S. competitors to gain access to their experimental medicines. Amgen executives are looking for Looking for In the context of general equities, this describing a buy interest in which a dealer is asked to offer stock, often involving a capital commitment. Antithesis of in touch with. promising experimental drugs to buy or help develop in return for a cut of the profit. Amgen officials flew to San Diego San Diego (săn dēā`gō), city (1990 pop. 1,110,549), seat of San Diego co., S Calif., on San Diego Bay; inc. 1850. San Diego includes the unincorporated communities of La Jolla and Spring Valley. Coronado is across the bay. last month to present to about 75 companies, one of several planned stops, Chief Financial Officer Richard Nanula Richard Nanula has served as Chief Financial Officer of Amgen Inc. (biotechnology) since August 2001 and as Executive Vice President since May 2001. On April 10, 2007 Amgen announced that he would be resigning from his position "to pursue other opportunities" He will be at Amgen told Bloomberg News. The Thousands Oaks-based company needs medicines that will help boost revenue over the next decade, investors said. Amgen has already said it will double last year's sales to $10 billion by 2005. Executives also traveled to Boston and Seattle and will visit the San Francisco San Francisco (săn frănsĭs`kō), city (1990 pop. 723,959), coextensive with San Francisco co., W Calif., on the tip of a peninsula between the Pacific Ocean and San Francisco Bay, which are connected by the strait known as the Golden area next, Nanula said. "I definitely expect to see more deals," said Eric Shen Shen, in the Bible, place, perhaps close to Bethel, near which Samuel set up the stone Ebenezer. , who manages about $350 million in the Pimco RCM RCM Reliability-Centered Maintenance RCM Royal College of Music RCM Royal Conservatory of Music RCM Royal Canadian Mint RCM Reliability Centered Maintenance RCM Revenue Cycle Management RCM Regional Climate Model RCM Ring-Closing Metathesis Biotechnology Fund. "Amgen is very comfortable and confident in returning growth through 2005. What they've been talking about in the last six months is how to grow beyond 2005." Researchers outside the company discovered the arthritis medicine Enbrel and Amgen's two most advanced experimental drugs, cinacalcet for dialysis patients and palifermin for a side effect of chemotherapy. "A slew of (Amgen's products) have come from reaching outside the company," Nanula said. "We're trying to kick it up a notch." Nanula, a former Walt Disney Co. executive who decorates his office with Mickey Mouse ears and other Disney items, said numerous small biotech companies approach Amgen about licensing agreements. The road trips are an attempt to improve access to the "cream of the crop," he said. "As successful as we are and as big as we are, we know that we're not going to continue to grow like we're currently growing without other people's products," he said. At a closing price of $65.73 on Aug. 27, Amgen shares were up 36 percent year to date, less than the 43 percent gain in the Nasdaq Biotechnology Index The NASDAQ Biotechnology Index includes securities of NASDAQ-listed companies classified according to the Industry Classification Benchmark as either Biotechnology or Pharmaceuticals which also meet other eligibility criteria. . In presentations, Amgen highlights the company's manufacturing capacity, sales force and its recent agreement to buy a stake in Tularik Inc., an unprofitable biotechnology company that specializes in the genetic causes of cancer, Nanula said. --Bloomberg News |
|
||||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion